Teva presents latest schizophrenia portfolio data including real-world outcomes with uzedy® (risperidone) showing lower rates of and longer time to relapse compared to oral treatment options and new phase 3 solaris data showing no incidence of pdss with tev-'749 (olanzapine) to date

Parsippany, n.j. and tel aviv, israel, may 30, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (hcru) data evaluating uzedy® (risperidone), an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, versus second-generation daily oral options. in the studies, patients receiving uzedy had lower rates of and longer time to relapse as well as better treatment adherence and persistence rates, fewer inpatient, outpatient and emergency department (ed) visits, shorter hospital length of stay and lower all-cause hcru. additionally, phase 3 solaris data show no incidence of post-injection delirium/sedation syndrome (pdss) to date in participants taking tev-'749, a once-monthly, long-acting injectable (lai) subcutaneous formulation of olanzapine. the systemic safety profile was consistent with approved olanzapine options. the data were presented at the 2025 psych congress elevate annual meeting, taking place from may 28-31, 2025, in las vegas, nevada.
TEVA Ratings Summary
TEVA Quant Ranking